BIOCON Fact Sheet, BIOCON Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

BIOCON Fact Sheet   (BICN)

Find Out: How to Find One Stock with Crorepati Potential?

Here is the latest financial fact sheet of BIOCON . For more details, see the BIOCON quarterly results and BIOCON share price and chart. For a sector overview, read our pharmaceuticals sector report.

BIOCON Price History

Price Rs 326.9
Mkt Cap Rs m 392,476
Vol '000 127.3
P/E X 40.1
P/CF X 23.9
EPS (TTM) Rs 8.2
1 Day % 0.1
No. of shares m 1,200.60
1 Week % 1.7
1 Month % -3.2
1 Year % -17.7
52 week H/L Rs 414.3/309.3
As on Jun 24, 2022 (Close)
* Results Consolidated

BIOCON Financials

No. of Mths
Year Ending
5-Yr Chart
Click to enlarge
High Rs1,1621,188718636488 
Low Rs482305544211275 
Sales per share (Unadj.) Rs193.068.691.952.559.2 
Earnings per share (Unadj.) Rs33. 
Diluted earnings per shareRs5. 
Cash flow per share (Unadj.) Rs47.513.624.212.113.7 
Dividends per share (Unadj.) Rs3.001.001.0000 
Adj. dividends per shareRs0.500.500.500.000.00 
Avg Dividend yield % 
Book value per share (Unadj.) Rs238.585.2100.355.062.3 
Adj. book value per shareRs39.742.650.154.962.2 
Shares outstanding (eoy) m200.00600.00600.001,200.001,200.00 
Bonus / Rights / Conversions  00000 
Price / Sales ratio x4.310. 
Avg P/E ratio x24.5103.737.856.549.4 
P/CF ratio (eoy) x17.354.826.135.027.9 
Price / Book Value ratio x3. 
Dividend payout %8.913.96.000 
Avg Mkt Cap Rs m164,430447,900378,645508,380457,350 
No. of employees `000NANANANANA 
Total wages/salary Rs m7,4709,31111,65314,58817,410 
Avg. sales/employee Rs Th00000 
Avg. wages/employee Rs Th00000 
Avg. net profit/employee Rs Th00000 
Net Sales Rs m38,60641,17155,14463,00571,058 
Other income Rs m1,5712,0624,1435,0756,052 
Total revenues Rs m40,17743,23359,28768,08077,110 
Gross profit Rs m9,7958,29113,18413,24513,145 
Depreciation Rs m2,7723,8514,4785,5227,151 
Interest Rs m260615709649577 
Profit before tax Rs m8,3345,88712,14012,14911,469 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m1,6161,5692,1233,1512,215 
Profit after tax Rs m6,7184,31810,0178,9989,254 
Gross profit margin %25.420.123.921.018.5 
Effective tax rate %19.426.717.525.919.3 
Net profit margin %17.410.518.214.313.0 
Current assets Rs m40,47741,48648,88553,25076,004 
Current liabilities Rs m16,78321,41330,38540,08042,101 
Net working cap to sales %61.448.833.520.947.7 
Current ratio x2. 
Inventory Days Days1651119583137 
Debtors Days Days8494867163 
Net fixed assets Rs m51,49056,47769,79287,508106,142 
Share capital Rs m1,0003,0003,0006,0006,000 
"Free" reserves Rs m46,70248,12357,20859,97068,728 
Net worth Rs m47,70251,12360,20865,97074,728 
Long term debt Rs m21,08217,89815,25612,22229,616 
Total assets Rs m91,96797,963118,677140,758182,146 
Interest coverage x33.110.618.119.720.9 
Debt to equity ratio x0. 
Sales to assets ratio x0. 
Return on assets % 
Return on equity %14.18.416.613.612.4 
Return on capital %12.59.417.016.411.5 
Exports to sales %00000 
Imports to sales %20.517.818.913.47.2 
Exports (fob) Rs m00000 
Imports (cif) Rs m7,8997,34810,3998,4745,084 
Fx inflow Rs m12,98812,05815,50611,75311,791 
Fx outflow Rs m7,8997,34810,3998,4745,084 
Net fx Rs m5,0894,7105,1073,2796,707 
From Operations Rs m 6,400 6,621 11,546 12,831 11,597 
From Investments Rs m -4,985 -6,840 -7,138 -15,589 -36,247 
From Financial Activity Rs m -1,775 -2,397 -2,417 3,876 25,640 
Net Cashflow Rs m -473 -2,612 2,103 1,654 723 
* Results Consolidated
Source: Accord Fintech, Equitymaster

Share Holding

Promoters 60.6%
Institution 24.0%
Non-Institution 15.4%
Total 100.0%
Free Float 39.4%
Pledged promoter holdings 0.0%
Shareholding as on Mar 2022

Company Information

Regd Off 20th Km, Hosur Road, Electronic City, Bengaluru - 560100
E-mail Web
Tel 080 2808 2808 Fax 080 2852 3423
Sector PHARMACEUTICALS Group Private sector
Tr Agent K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.), Karvy Selenium Tower B Plot 31-32, Gachibowli Financial District, Nanakramguda
Auditor S. R. Batliboi & Assoc.
CHM: Kiran Mazumdar-Shaw COMP SEC: Mayank Verma YEAR OF INC: 1978 BSE CODE: 532523 FV (Rs): 5 DIV YIELD (%): -

Read: BIOCON 2020-21 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    


Yellow Ad


A One Stock Gift in 1990 Turns into Rs 130 Crores

In 2017, Ravi made headlines by calling a leading business news channel with a surprising announcement - his grandfather had left him 20,000 shares of only one stock.

And on the day of his call - these shares were worth Rs 130 crore.

Can you guess which is this company?

It's MRF.

Ravi's story is one of the amazing stories of becoming Crorepati from a single stock.

But the question is, how to find that one stock with crorepati potential?

To find the answer to this million-dollar question, join our 'One Stock Crorepati' MEGA summit on 30th June, where we will reveal details of what we call a potential 'crorepati' stock...

Learn more

Today's Market

Sensex Zooms 462 Points, Nifty Ends Near 15,700; Auto & FMCG Stocks Rally(Closing)

Indian share markets ended the week on a firm note tracking positive global cues.

Views on news

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks (Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Why Tata Power Share Price is Falling (Views On News)

Jun 14, 2022

Here's why shares of Tata Power have fallen in recent days.

Is it Time to Start Buying Stocks Selectively? (Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

Best Monopoly Stocks to Own in 2022 Views On News (Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

When Will the Stock Market Recover? (Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms